EPA's Dioxin Assessment May Overstate Risk of Cancer

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 15 No 8
Volume 15
Issue 8

An evaluation of the US Environmental Protection Agency's most recent assessment of dioxin has concluded that EPA understated the uncertainly about the chemical's health risks and may have overstated the risk of human cancer.

WASHINGTON—An evaluation of the US Environmental Protection Agency's most recent assessment of dioxin has concluded that EPA understated the uncertainly about the chemical's health risks and may have overstated the risk of human cancer. The report by the National Research Council (NRC) found that EPA provided a comprehensive review of the scientific data but failed to sufficiently quantify the risks or adequately justify the assumptions used to support them. The NRC is the research arm of the National Academy of Sciences and National Academy of Engineering.

Dioxin—its most toxic form is TCDD, found in the herbicide Agent Orange—and dioxin-like compounds enter the environment from several sources, which include combustion, metal processing, and chemical manufacturing and processing. Human exposure to the chemicals occurs most often through the consumption of beef, pork, fish, and dairy products. Occupational or accidental exposure can cause far higher exposure levels than occur through the food chain. However, evidence suggests that human exposure to dioxin and dioxin-like chemicals has declined in recent years.

In 1985, EPA classified dioxin as a "probable human carcinogen," and in 1997, the WHO's International Agency for Research on Cancer designated dioxin as "carcinogenic to humans." Five years ago, the National Toxicology Program upgraded its classification of dioxin to "carcinogenic in humans," and the EPA in its 2003 draft reassessment raised the classification of TCDD to "known to cause human cancer."

EPA had used a "linear" model to determine risk based on higher-dose exposure data from exposed workers, an approach that usually results in higher risk estimates than those using nonlinear models where biologic responses do not vary proportionally with dose. The report recommended that EPA use both nonlinear and linear methods to assess risk, including compelling new animal data released after the EPA completed its 2003 reassessment. The new data, combined with substantial evidence that dioxin does not directly damage DNA, provides an adequate justification for using nonlinear methods to estimate human cancer risks of dioxin at relatively low levels of exposure, the report stated. The panel did agree unanimously that TCDD fits the definition for likely to be carcinogenic to humans, and it added that the public health implications of the two terms appear identical. Nonetheless, members urged EPA to reconsider whether its 2003 classification of TCDD as carcinogenic to humans met its 2005 cancer guidelines.

Recent Videos
9 Experts are featured in this series.
Vinay K. Puduvalli, MD, is featured in this series.
Genetic consultation and next-generation sequencing can also complement treatment strategies for patients with pancreatic cancer.
An advanced computation linguistics model that can detect pancreatic cysts can help patients prevent pancreatic tumors from forming.
Brett L. Ecker, MD, focused on the use of de-escalation therapy, which is gaining momentum in neuroendocrine tumors.
Immunotherapy options like CAR T-cell therapy and antigen-presenting cell-directed agents are currently being evaluated in the pancreatic cancer field.
Certain bridging therapies and abundant steroid use may complicate the T-cell collection process during CAR T therapy.
Pancreatic cancer is projected to become the second-leading cause of cancer-related deaths by 2030 in the United States.
Related Content